dc.contributor.author | Vormoor, B | |
dc.contributor.author | Veal, GJ | |
dc.contributor.author | Griffin, MJ | |
dc.contributor.author | Boddy, AV | |
dc.contributor.author | Irving, J | |
dc.contributor.author | Minto, L | |
dc.contributor.author | Case, M | |
dc.contributor.author | Banerji, U | |
dc.contributor.author | Swales, KE | |
dc.contributor.author | Tall, JR | |
dc.contributor.author | Moore, AS | |
dc.contributor.author | Toguchi, M | |
dc.contributor.author | Acton, G | |
dc.contributor.author | Dyer, K | |
dc.contributor.author | Schwab, C | |
dc.contributor.author | Harrison, CJ | |
dc.contributor.author | Grainger, JD | |
dc.contributor.author | Lancaster, D | |
dc.contributor.author | Kearns, P | |
dc.contributor.author | Hargrave, D | |
dc.contributor.author | Vormoor, J | |
dc.date.accessioned | 2017-03-24T14:15:24Z | |
dc.date.issued | 2017-06-01 | |
dc.identifier.citation | Pediatric blood & cancer, 2017, 64 (6) | |
dc.identifier.issn | 1545-5009 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/494 | |
dc.identifier.eissn | 1545-5017 | |
dc.identifier.doi | 10.1002/pbc.26351 | |
dc.description.abstract | Aurora kinases regulate mitosis and are commonly overexpressed in leukemia. This phase I/IIa study of AT9283, a multikinase inhibitor, was designed to identify maximal tolerated doses, safety, pharmacokinetics, and pharmacodynamic activity in children with relapsed/refractory acute leukemia. The trial suffered from poor recruitment and terminated early, therefore failing to identify its primary endpoints. AT9283 caused tolerable toxicity, but failed to show clinical responses. Future trials should be based on robust preclinical data that provide an indication of which patients may benefit from the experimental agent, and recruitment should be improved through international collaborations and early combination with established treatment strategies. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | WILEY | |
dc.subject | Humans | |
dc.subject | Leukemia | |
dc.subject | Acute Disease | |
dc.subject | Urea | |
dc.subject | Benzimidazoles | |
dc.subject | Neoplasm Proteins | |
dc.subject | Protein Kinase Inhibitors | |
dc.subject | Maximum Tolerated Dose | |
dc.subject | Adolescent | |
dc.subject | Child | |
dc.subject | Child, Preschool | |
dc.subject | Infant | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Aurora Kinases | |
dc.title | A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-10-07 | |
rioxxterms.versionofrecord | 10.1002/pbc.26351 | |
rioxxterms.licenseref.startdate | 2017-06 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Pediatric blood & cancer | |
pubs.issue | 6 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical PD Biomarker Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical PD Biomarker Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical PD Biomarker Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical PD Biomarker Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 64 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical PD Biomarker Group | |
icr.researchteam | Clinical Pharmacology – Adaptive Therapy | |
icr.researchteam | Medicine Drug Development Unit (de Bono) | |
dc.contributor.icrauthor | Banerji, Udai | |
dc.contributor.icrauthor | Swales, Karen | |